Speakers

Expand/Collapse

Andrew Pierce
Vice President - Translational Biology
Crescendo Biologics

Day One

Wednesday,  January 26 2022

2:00 pm | Primary Pharmacology of CB213, a LAG-3-PD1 Co-targeting Humabody™

Day Two

Thursday, January 27 2022

9:30 am | Panel Discussion: Tug of War: Understanding How LAG-3 & PD-1 Interplay with One Another

Creg Workman
Research Assistant
University of Pittsburgh

Day Two

Thursday, January 27 2022

12:15 pm | How does LAG-3 mediate its inhibitory function?

Ella Ioffe
Director
Regeneron Pharmaceuticals

Day One

Wednesday,  January 26 2022

1:30 pm | Targeting LAG-3 in Cancer Immunotherapy: Advancing Beyond PD-1 Blockade

Day Two

Thursday, January 27 2022

2:15 pm | Panel Discussion: Compare Bispecific & Combination Therapeutic Approaches

Frederic Triebel
Chief Scientific Officer & Chief Medical Officer
Immutep

Day One

Wednesday,  January 26 2022

12:00 pm | My Journey Through the LAG-3/MHC Class II Landscape: 1988-2021

Giuseppe Gullo
Clinical Lead
Regeneron Pharmaceuticals

Day Two

Thursday, January 27 2022

10:15 am | Bridging Preclinical & Clinical Worlds

Jessica Chacon
Assistant Professor
Texas Tech University Health Sciences Center

Day Two

Thursday, January 27 2022

9:30 am | Panel Discussion: Tug of War: Understanding How LAG-3 & PD-1 Interplay with One Another

Jon Piganelli
Associate Professor School of Medicine
University of Pittsburgh

Laura Codari Deak
Team & Research Project Leader, Principal Scientist
Roche Innovation Center

Day One

Wednesday,  January 26 2022

9:30 am | A Novel Bispecific Checkpoint Inhibitor Antibody to Preferentially Block PD-1 & LAG-3 on TILs Whilst Sparing Treg Activation

Laurel Mckee
Scientist & Senior Associate - Research
L Hoffman La Roche

Day One

Wednesday,  January 26 2022

2:30 pm | Roche CDx is now Personalised Healthcare Solutions

Marc Voigt
Chief Executive Officer
Immutep

Day One

Wednesday,  January 26 2022

9:00 am | Opening Remarks: Reviewing the Past 12 Months of LAG-3 Therapeutic Development

Maurizio Pellecchia
Professor of Biomedical Sciences Daniel Hays Endowed Chair in Cancer Research Director, Center for Molecular and Translational Medicine
UCR School of Medicine

Michelle Morrow
VP, Preclinical Translational Pharmacology
F-Star Biotechnology

Day One

Wednesday,  January 26 2022

11:00 am | Rescuing Checkpoint Inhibitor FS118

Paul Moore
Vice President - Immunology & Cell Biology
MacroGenics

Day One

Wednesday,  January 26 2022

11:30 am | Advancing Tebotelimab, a Bispecific PD-1 x LAG-3 DART Molecule, From Concept to Clinical Assessment

Day Two

Thursday, January 27 2022

9:30 am | Panel Discussion: Tug of War: Understanding How LAG-3 & PD-1 Interplay with One Another

Richard Wu
Professor
Ohio State University

Day Two

Thursday, January 27 2022

2:15 pm | Panel Discussion: Compare Bispecific & Combination Therapeutic Approaches

Sarah Lauder
Research Associate
Cardiff University

Day Two

Thursday, January 27 2022

12:45 pm | Sequential Targeting of PI3Kd & LAG-3 as an Effective Anti- Cancer Approach

Segundo Gonzalez
Leader
Universidad de Oviedo

Day Two

Thursday, January 27 2022

9:00 am | LAG-3 Blockade with Relatlimab Restores Anti Leukemic Immune Response in Chronic Lymphocytic Leukemia

Shuqi Zeng
Senior Director
Medical Epimab Biotherapeutics

Day One

Wednesday,  January 26 2022

3:25 pm | Phase I Dose Escalation Experience Of EMB-02 (a PD-1/ LAG-3 bsAb) In Multiple Countries (US, China & Others) Simultaneously

Xiaobo Mao
Associate Professor
Johns Hopkins School of Medicine

Day Two

Thursday, January 27 2022

2:45 pm | The role of LAG-3 in Mediating Alpha-Synuclein Pathology in Parkinson’s Disease

Yvonne Saenger
Director of Melanoma Immunotherapy
Columbia University

Day Two

Thursday, January 27 2022

2:15 pm | Panel Discussion: Compare Bispecific & Combination Therapeutic Approaches